<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117129</url>
  </required_header>
  <id_info>
    <org_study_id>ML21826</org_study_id>
    <secondary_id>2008-002381-55</secondary_id>
    <nct_id>NCT01117129</nct_id>
  </id_info>
  <brief_title>A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)</brief_title>
  <official_title>Efficacy of MabThera in Patients With Rheumatoid Arthritis, by Measurement of Disease Parameters Through Magnetic Resonance of the Hand (RESONAR Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo controlled, parallel group study will assess the
      efficacy and safety of rituximab [MabThera/Rituxan] in patients with severe active rheumatoid
      arthritis refractory to at least one anti-TNF treatment, using magnetic resonance imaging
      (MRI) of the hand for efficacy measurement. Patients will be randomized to receive 2
      intravenous infusions 14 days apart of either 1000mg MabThera (group A) or placebo (group B).
      All patients will receive methotrexate 10-25mg weekly. Patients in group A demonstrating
      clinical response at week 24 may receive further cycles of MabThera, patients in group B
      without clinical response will also be treated with active MabThera. Anticipated time on
      study treatment is up to 2 years. Target sample size is &lt;50 patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was prematurely terminated as 2 patients were recruited and both of them withdrawn
    from the study before reaching the primary end point.
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone erosion score on magnetic resonance imaging (MRI) using the rheumatoid arthritis magnetic resonance imaging scoring system (RAMRIS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Synovitis score on MRI using RAMRIS</measure>
    <time_frame>months 6, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone edema score on MRI using RAMRIS</measure>
    <time_frame>months 6, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone erosion score on MRI using RAMRIS</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to DAS28-CRP</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender or swollen joint count (ACR criteria)</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health assessment questionnaire (HAQ)</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab [MabThera/Rituxan]</intervention_name>
    <description>1000 mg by i.v. infusion on day 1 and 15</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>i.v. infusion on day 1 and 15</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>10-25 mg weekly</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab [Mabthera/Rituxan]</intervention_name>
    <description>1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, 18-75 years of age

          -  active rheumatoid arthritis (DAS28-CRP&gt;3.2)

          -  refractory to one or more anti-TNF

          -  on stable treatment for RA for &gt;/=4 weeks

          -  evidence of erosive disease and/or synovitis in wrist and/or knuckles

        Exclusion Criteria:

          -  active systemic or local infection

          -  previous or current history of any demyelinization process in central nervous system,
             pancytopenia or aplasic anaemia

          -  signs of immunodeficiency, HIV infection or tuberculosis

          -  contraindications to MRI, such as metal devices, claustrophobia, moderate or severe
             renal insufficiency, or allergy to contrast agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

